Prostaglandin E₁ and arterial occlusive disease: pharmacological considerations

Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects

“…After normalization by dose ofPGE1, comparable maximum plasma concentrations of 15-keto -PGE0 were found with the additional information of a pharmacokinetic profile. Our results are consistent with published data [14]. Hamberg and Samuelsson [15], using administered [3H]-PGEz, estimated plasma concentrations of 15-keto-PGE0 after chromatography and determination of radioactivity by scintillation counting.…”

Accelerated Blood Clearance Phenomenon Upon Repeated Injection of PEG-modified PLA-nanoparticles

“…While various clinical treatments, such as vascular bypass surgery, have been developed for these diseases, the prognosis is still not good. Prostaglandin E 1 (PGE 1 ), which has various physiological actions, such as vasodilation, angiogenesis and inhibition of platelet aggregation, serves as an effective treatment for peripheral obstructive vascular diseases (20)(21)(22). However, when administered systemically, PGE 1 also has related adverse effects, such as hypotension and diarrhea (21,23).…”

Synthesis of Prostaglandin E1 Phosphate Derivatives and Their Encapsulation in Biodegradable Nanoparticles

“…Results from a number of clinical and animal studies support this notion (3)(4)(5). However, the range of activities of PGE 1 are also related to adverse effects (such as hypotension and diarrhea) due to its distribution throughout the body when administered systemically (4,6). Furthermore, in addition to its chemical instability (hydrolysis to PGA 1 ), PGE 1 is easily inactivated by 15-hydroxydehydrogenase during the passage through the lung (7)(8)(9).…”

“…Results from a number of clinical and animal studies support this notion (3)(4)(5). However, the range of activities of PGE 1 are also related to adverse effects (such as hypotension and diarrhea) due to its distribution throughout the body when administered systemically (4,6).…”